A unique type of GSK-3 inhibitor brings new opportunities to the clinic
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
A substrate peptide that the kinase GSK-3 converts into its own inhibitor improves symptoms and cognitive function in an Alzheimer’s disease model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 4×
“The 5XFAD mouse model and behavior tests 5XFAD transgenic mice (60) were purchased from Jackson Laboratories.”
BackgroundMethodInfluentialAn Overview of Autophagy: Morphology, Mechanism, and Regulation
Parzych, K. R., & Klionsky, D. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5371 · Cited by 2,521
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 1×
“This type of inhibitor, although powerful, often has limited specificity (2, 3), because the ATP binding site is highly conserved among protein kinases (4, 5).”
BackgroundMolecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
Object recognition test in mice
Leger, M., Quiedeville, A., Bouet, V., Haelewyn, B., Boulouard, M., Schumann-Bard, P., & Freret, T. (2013) · Nature Protocols · doi:10.1038/nprot.2013.155 · Cited by 1,357
Lee, J.-H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., et al. (2010) · Cell · doi:10.1016/j.cell.2010.05.008 · Cited by 1,212 · cited 2×
“Pro(8) Phe(67) (22) Ala(3) (18) — Val(214) (55) Pro(5) (8) Arg(92)hydr (54) Phe(93) (40) Pro(4) (52) Pro(5) (89) Phe(67) (45) Val(87)(27) Phe(93) (97) Pro(4) (29) Pro(5) (25) — —”
BackgroundThe GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease
Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965 · cited 1×
“We then dissected hippocampal tissues and measured the abundance of b-catenin and the amount of tau phosphorylation at Ser(396), which is a site-phosphorylated GSK-3 (17, 57, 58).”
BackgroundTransport of drugs from the nasal cavity to the central nervous system
Illum, L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00087-7 · Cited by 907 · cited 4×
“route is an effective delivery route for L803mts and other peptide-based compounds (28, 30, 55, 56).”
BackgroundInfluentialThe amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814 · cited 1×
“Ser(6)/Ser(6)(p) ATP P g (72) Asp(181) (87) Lys(183) (77) Lys(203) (50) ATP P g (93) Asp(181) (50) Lys(183) (100) Ser(219) (98) Lys(94) (91) Arg(96) (100) Arg(180) (100) Lys(205) (100) Arg(96) (100) Arg(180) (100) Lys(205) (100) Arg(96) (100) Arg(180) (86) Lys(205) (99) Lys(1) (91) Lys(183) (98) Lys(183) (92) Gln(185)…”
Automated apparatus for quantitation of social approach behaviors in mice
Nadler, J. J., Moy, S. S., Dold, G., Trang, D., Simmons, N., Perez, A., Young, N. B., Barbaro, R. P., Piven, J., Magnuson, T. R., et al. (2004) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2004.00071.x · Cited by 775 · cited 3×
“Sociability was evaluated according to Crawley’s sociability test using the threechamber paradigm (68).”
MethodInfluentialHanger, D. P., Hughes, K., Woodgett, J. R., Brion, J.-P., & Anderton, B. H. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90774-2 · Cited by 737 · cited 3×
“For example, GSK-3 phosphorylates the microtubule-associated protein tau (17, 18), and phosphorylated tau causes neurofibrillary tangle formation in AD (19, 20).”
BackgroundProteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process
De Strooper, B. (2010) · Physiological Reviews · doi:10.1152/physrev.00023.2009 · Cited by 455 · cited 1×
“Pro(7) Ile(217) (64) Tyr(216)ring (71) Ala(3) (15) Ile(217) (82) Tyr(216)ring (98) Pro(5) (5) Pro(11) (92) Phe(67) (11) Phe(93) (90) Pro(5) (10) Arg(96)hydr (44) Tyr 216 ring (98) Ile(217) (15) Lys(1)hydr (75) Tyr(216)ring (99) Ile(217) (45)”
GSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes
Ly, P. T. T., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., Zhang, M., Yang, Y., Cai, F., Woodgett, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64516 · Cited by 442
A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368
Temporal memory deficits in Alzheimer’s mouse models: Rescue by genetic deletion of BACE1
Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W. L., Vassar, R., & Disterhoft, J. F. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04551.x · Cited by 298
Astrocytes Regulate Microglial Phagocytosis of Senile Plaque Cores of Alzheimer's Disease
DeWitt, D. A., Perry, G., Cohen, M., Doller, C., & Silver, J. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6738 · Cited by 261
Crawley, J. N., Chen, T., Puri, A., Washburn, R., Sullivan, T. L., Hill, J. M., Young, N. B., Nadler, J. J., Moy, S. S., Young, L. J., et al. (2007) · Neuropeptides · doi:10.1016/j.npep.2007.02.002 · Cited by 232
Li, T., & Paudel, H. K. (2006) · Biochemistry · doi:10.1021/bi051634r · Cited by 140
Hurtado, D. E., Molina-Porcel, L., Carroll, J. C., MacDonald, C., Aboagye, A. K., Trojanowski, J. Q., & Lee, V. M.-Y. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0889-12.2012 · Cited by 126
Cited by
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Xue, C., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 281
Activating Wnt/β-catenin signaling pathway for disease therapy: Challenges and opportunities
Huang, P., Yan, R., Zhang, X., Wang, L., Ke, X., & Qu, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.008 · Cited by 268
Wnt signaling deregulation in the aging and Alzheimer’s brain
Palomer, E., Buechler, J., & Salinas, P. C. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00227 · Cited by 237
Alzheimer’s disease as an inflammatory disease
Bolós, M., Perea, J. R., & Avila, J. (2017) · BioMolecular Concepts · doi:10.1515/bmc-2016-0029 · Cited by 216
“In this way, tau toxicity could result in an inflammatory process that could be prevented by the inhibition of tau kinases, like GSK3 (77).”
Background
Metadata
- Authors
- Licht-Murava, A., Paz, R., Vaks, L., Avrahami, L., Plotkin, B., Eisenstein, M., & Eldar-Finkelman, H.
- Venue
- Science Signaling
- Published
- 2016-11-15
- Volume
- 9
- Issue
- 454
- Pages
- ra110-ra110
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W2554268713
- Cited by
- 75
- References
- 23
- FWCI
- 6.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.